What does GHK-Cu stand for?

GHK-Cu refers to the copper-bound form of the tripeptide glycyl-L-histidyl-L-lysine. GHK is shorthand for the three amino acids in the peptide: glycine, histidine, and lysine. The Cu suffix denotes the copper(II) ion complexed with the peptide. The compound is sometimes called the copper peptide or copper tripeptide.

Is GHK-Cu naturally occurring in the human body?

Yes. GHK-Cu appears naturally in human blood plasma, saliva, urine, and cerebrospinal fluid. It is thought to arise partly as a breakdown product of larger proteins during tissue injury and remodeling. Published research has reported that plasma GHK concentrations are higher in younger adults and decline with age, though the functional significance of that decline in human aging has not been fully established.

How does GHK-Cu differ from BPC-157 and TB-500?

All three compounds have been studied in healing and tissue remodeling contexts, but they are structurally different and act through different proposed mechanisms. BPC-157 is derived from a stomach protein and has the strongest preclinical literature in gut and tendon repair. TB-500 is a synthetic fragment of thymosin beta-4 with research concentrated in cardiovascular and musculoskeletal contexts. GHK-Cu is a copper-binding tripeptide with research focused on skin, wound healing, and collagen biology. The three compounds are sometimes used together in research contexts, but there is no published controlled trial data on combination effects.

Is GHK-Cu approved by the FDA?

No. GHK-Cu has no FDA approval for any injectable indication. Topical copper peptide formulations are sold legally as cosmetic ingredients, which are regulated for safety but not for efficacy the way pharmaceutical drugs are. Injectable GHK-Cu is available only as a research chemical, without the quality controls, clinical trial record, or prescribing information that come with an approved pharmaceutical product.

Is there a safety concern about the copper component?

Copper toxicity is a real concern at high doses, but GHK-Cu research typically involves very small amounts of copper delivered in the peptide complex rather than free ionic copper. The published safety profile from topical and animal studies does not indicate copper toxicity signals at doses used in those studies. Systemic injectable research in humans is limited enough that a comprehensive safety characterization from clinical trials does not yet exist for the injectable route.

GHK-Cu: Copper Peptide Research and the Biology of Tissue Remodeling

Published: April 29, 2026•Updated: April 29, 2026

Research use only. This article discusses compounds that include approved medications, investigational drugs, and research peptides. Material sold for research is not cleared for human administration and is not a substitute for medical advice.

GHK-Cu is a copper-binding tripeptide that occurs naturally in human blood plasma, saliva, and urine. It was identified through biochemical research in the early 1970s and has since been studied across a broad range of contexts, from wound healing and collagen synthesis to skin aging and hair follicle biology. Unlike most research peptides in this space, GHK-Cu also has an established commercial presence in topical cosmetics, where copper peptide formulations have been marketed for decades. This article covers what the compound is, where the published research is strong, where it is preliminary, and how the topical and injectable research contexts differ.

What GHK-Cu is

GHK-Cu is the stable complex formed when the tripeptide glycyl-L-histidyl-L-lysine (GHK) binds to a copper(II) ion. The tripeptide is a naturally occurring molecule found in human blood plasma, saliva, urine, and cerebrospinal fluid. It appears to be a breakdown fragment of larger proteins, including albumin and collagen precursors, released during tissue injury and remodeling.

The compound was first identified by biochemist Loren Pickart, who published research in 1973 describing a serum fraction from young human plasma that stimulated liver cell regeneration in aging tissue preparations. Subsequent work identified the active component as the GHK tripeptide and characterized its copper-binding properties. Pickart continued researching GHK-Cu for several decades, and much of the foundational literature on the compound comes from his laboratory.

One distinguishing feature is that GHK-Cu levels in plasma appear to decline with age. Research suggests plasma GHK concentrations are measurably higher in young adults than in older populations, with a gradual reduction across the decades. Whether this decline is a driver of age-related tissue repair deficits or simply a correlate of them remains an open question, but it has motivated research interest in GHK-Cu as a possible restorative signal.

The copper component matters

Copper(II) is an essential cofactor for several enzymes involved in connective tissue formation and antioxidant defense, including lysyl oxidase, superoxide dismutase, and cytochrome c oxidase. The GHK peptide has measurable biological activity on its own in some assays, but the copper-bound form shows substantially greater activity in wound healing and collagen-promoting studies. The two terms are sometimes used interchangeably in the literature, but GHK-Cu, the copper-complexed form, is the subject of most wound healing and tissue remodeling research.

Proposed mechanisms of action

The mechanistic picture for GHK-Cu is more complex than for most research peptides because the compound appears to influence biology through several converging pathways rather than through a single well-defined receptor. This makes it harder to characterize cleanly but also partly explains why it has attracted research interest across different tissue types.

•Copper transport: GHK-Cu may deliver ionic copper to local tissue environments, supporting the activity of copper-dependent enzymes involved in extracellular matrix formation and antioxidant defense
•Collagen synthesis activation: in vitro studies have shown GHK-Cu stimulates fibroblasts to produce collagen and other extracellular matrix proteins, including elastin and glycosaminoglycans
•Growth factor modulation: laboratory research has described interactions between GHK-Cu and growth factor signaling pathways involved in wound repair, including effects on fibroblast activation and migration
•Anti-inflammatory activity: GHK-Cu has been reported to reduce the expression of inflammatory signaling molecules in cell culture models
•Antioxidant effects: stimulation of superoxide dismutase activity and other antioxidant pathways has been reported in preclinical research

Pickart's later research used bioinformatic approaches to analyze how GHK-Cu-associated gene expression changes compared with large databases of disease-associated gene signatures. He proposed that the compound modulates hundreds of genes relevant to aging, DNA repair, inflammation, and cancer biology. These analyses are scientifically interesting and have generated considerable attention, but bioinformatic studies produce hypotheses rather than clinical evidence. The question of whether administering GHK-Cu produces these effects in humans at therapeutic doses has not been fully answered by interventional trials.

Wound healing research

The original and arguably strongest evidence base for GHK-Cu is in wound healing. Animal model research conducted from the 1970s onward showed that topical and locally administered GHK-Cu could accelerate wound closure, improve collagen organization in healing tissue, and stimulate the formation of new blood vessels in the wound bed. These effects were reproduced across multiple animal species and wound types.

Animal model studies

Preclinical wound healing research showed GHK-Cu could accelerate wound contraction rates, increase collagen deposition in healing tissue, improve tensile strength of healed wounds, and promote angiogenesis. Effects were observed with both topical application and local subcutaneous administration. These results provided the mechanistic rationale for later human research.

Human wound studies

A number of smaller human studies examined topical GHK-Cu formulations applied to surgical wounds, chronic wounds, and aged skin. Results generally showed improvements in wound closure speed and tissue quality measures compared with control formulations. Study quality varied, and most trials were small and industry-funded, limiting the weight placed on any single result.

Collagen and ECM endpoints

Several human studies measured skin biopsy markers of collagen and extracellular matrix content after topical GHK-Cu treatment. Published results reported increased collagen density and changes in matrix protein expression consistent with a tissue-remodeling effect. These biopsy-level findings support the mechanism proposed from cell culture studies, though translation to injectable applications requires separate data.

The wound healing evidence base is primarily built on topical application studies, which is also how the compound moves into regulated commercial products. Wound healing research in this form has clearer regulatory and translational pathways than injectable research, and several wound care formulations incorporating copper peptides have been developed and commercialized. The injectable research context, by contrast, has a much thinner published literature.

Skin remodeling and cosmetic research

GHK-Cu is one of the more thoroughly studied active ingredients in cosmetic dermatology, though the research context is different from pharmaceutical clinical trials. Cosmetic ingredient studies are typically funded by manufacturers, conducted in smaller populations, and use outcome measures specific to skin appearance rather than clinical disease endpoints. With those caveats in place, the published cosmetic literature on GHK-Cu is more extensive than what exists for most other peptide compounds.

Published studies on topical GHK-Cu formulations have reported improvements in skin thickness, elasticity, and wrinkle depth over treatment periods ranging from several weeks to a few months. Facial skin studies have described reductions in fine lines, improvements in skin firmness, and changes in skin surface texture. Histological studies accompanying some of these trials showed increased collagen and elastin fiber content in skin biopsies from treated areas.

Interpreting cosmetic research

Industry-funded cosmetic trials are subject to publication bias and study design limitations that make their results harder to interpret than independent pharmaceutical trials. However, the biological plausibility for GHK-Cu in skin is reasonably strong. The compound stimulates fibroblast collagen production in cell culture, copper is essential for lysyl oxidase which crosslinks collagen fibers, and the proposed mechanisms connect directly to the outcomes measured in skin studies. The convergence of mechanistic rationale with consistent directional findings across multiple studies is more reassuring than either line of evidence alone.

Translation from topical to injectable evidence is not automatic. Topical GHK-Cu penetrates skin primarily into the dermis, where fibroblasts and collagen-producing cells are located. Systemic injectable GHK-Cu distributes differently and faces different clearance kinetics. Whether the skin remodeling effects seen with topical application would persist, increase, or change character with systemic administration is a question the published literature does not yet answer clearly.

Hair follicle and other research areas

Beyond wound healing and skin remodeling, GHK-Cu has been studied in several other contexts with varying degrees of evidence behind each.

Hair follicle biology

GHK-Cu has been examined in hair follicle research, where it is thought to influence the dermal papilla cells that regulate follicle cycling. In vitro research showed stimulatory effects on follicle size and proliferative markers. Some topical hair product research has reported effects on hair thickness and follicle density. The evidence is preliminary relative to established hair loss treatments but has generated enough interest for continued investigation.

Neuroprotection

Some preclinical research has examined whether GHK-Cu has neuroprotective properties, motivated by the copper cofactor role in enzymes involved in oxidative stress management in neural tissue. Animal model studies have reported effects on nerve repair and recovery from neural injury. Human interventional data in this area is minimal.

Pulmonary research

Pickart and colleagues proposed GHK-Cu as a research candidate for pulmonary conditions including fibrosis, based on bioinformatic analyses showing its gene expression signature was inversely related to fibrosis-associated gene programs. This remains a hypothesis-generating rather than trial-supported area of research.

Anti-inflammatory applications

GHK-Cu has shown anti-inflammatory properties in cell culture models, reducing the expression of inflammatory cytokines under various challenge conditions. Published preclinical data covers skin inflammation, wound site inflammation, and some systemic models. The gap between these in vitro results and clinical applications in inflammatory disease has not yet been bridged by human trials.

Regulatory status and form factor context

GHK-Cu occupies an unusual position compared with other research compounds discussed on this site because it exists across two very different regulatory worlds simultaneously. As a cosmetic ingredient, copper peptides including GHK-Cu are legal, commercially available, and sold in branded skincare products without prescription. This topical cosmetic market has existed for decades and is not a research-only phenomenon.

The injectable form of GHK-Cu is a different matter. There is no approved pharmaceutical product containing GHK-Cu for any indication in the United States or major regulatory jurisdictions. Injectable GHK-Cu is available from research peptide suppliers in the same category as other unapproved research compounds, sold for laboratory and research purposes only. The quality, purity, and identity of material from these sources cannot be confirmed without independent analytical testing, and there is no prescribing information or dosing guidance from a regulatory review process.

GHK-Cu is not specifically listed on the WADA Prohibited List. The compound is not a peptide hormone, growth factor, or anabolic agent in the categories explicitly covered. Athletes subject to anti-doping rules should still review the current annual list and their sport-specific regulations, since regulatory categories can evolve and some general category descriptions may capture compounds not listed by name.

The cosmetic research literature, while valuable for understanding mechanisms, does not substitute for pharmaceutical-grade clinical trial evidence. Wound healing and skin remodeling effects from topical application are supported by a reasonable body of published work. The systemic injectable use case has a much thinner evidence base, and anyone considering GHK-Cu as an injectable research peptide should weigh the substantial asymmetry between what is known from topical studies and what is documented for systemic administration.